CD8A and metastatic melanoma: The biopsy analysis of metastatic melanoma patients showed that selectively inhibiting BRAF with PLX4720 or GSK2118436 induced abundant CD8+ T cells in tumors, which provided powerful support for combining BRAF inhibitors with immunotherapy (71).